Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — Investor Presentation (February 2005)
26 slides from Dyadic International's investor presentation, Feb 22, 2005
Slide 1: Dyadic International, Inc. - Commercializing Proteins
D1) eee lt Dyadic International, Inc. “Commercializing Proteins” Mark Emalfarb, CEO February 22, 2005
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and discussion may contain information that includes or is based upon certain “forward-looking statements” relating to our business. Actual results, as well as the Company's business strategy, could vary significantly. For a discussion of the factors that
Slide 3: Company Highlights
Company Highlights e Experienced, success tested management team and Scientific Advisory Board e Patented C1 Host Technology enables discovery, development and manufacturing of protein products using a single cell line + Making a variety of products more reliably and affordably e Established Industr
Slide 4: Company history since 1979
e Founded in 1979 e Pioneered major advances in the use of cellulases in stone wash processes e Developed and manufactured proprietary and patented specialty enzymes e Isolated C1 (Chrysosporium lucknowense), a filamentous fungus from soil Improved C1’s oe and screening capabilities to form the nucl
Slide 5: Dyadic Overview
Dyadic Overview Developing DNA Products For Diverse Billion Dollar Global Markets Commercial Industrial Therapeutic
Slide 6: Target markets and product opportunities
Phase 1 Phase 2 Phase 3 Target Markets Industrial Agricultural Chemical | Pharmaceutical} Other Market Segments and “Textiles “Animal Feed *Pulp & Paper | «Biogenerics: “Biofuels Product Opportunities -EPO “Cellulose to ‘Animal Heath | Specialty - Enbrel ethanol *Starch Chemicals -IL-6 conversion *A
Slide 7: C1 Host Technology
C1 Host Technology
Slide 8: Testimonial
Testimonial Scientists at Dyadic, based in Jupiter, FL may have discovered the holy grail in the form of a lowly fungus ... By using a single organism for all steps of the process, Dyadic has been able to eliminate many of the bottlenecks inherent with other technologies. G. Steven Burrill CEO, Burr
Slide 9: C1 Screening System
C1 Screening System + C1used in HTS equipment, micro-titer wells (1 mL) — : eu ic genes and their proteins e C1 Expression System o Eis pe is ab nae te vanes oy recombinant protein products St 156,000 L
Slide 10: High Level Integrated Protein Production
High Level Integrated Protein Production C1 Expression System Advantages: Microtiter wells through 150,000 L fermentors Favorable glycosylation Eukaryotic genes Greater and faster expression Favorable fermentation characteristics | Rapid, reliable commercial scale up ra cape
Slide 11: C1 Genome Sequencing
C1 Genome Sequencing* » Expect to identify up to 12,000 genes » Turn novel genes into new protein and enzyme products » Further optimize C1 Host Technology to make new products + Improve versatility, efficiency and yield by identifying and modifying key genes involved in expression
Slide 12: Industrial Enzymes Business
Industrial Enzymes Business 12
Slide 13: $2.0 billion market - Pulp & Paper
$2.0 billion market - Pulp & Paper* e Untapped market e Address major industry issues in three main market segments » bio-bleaching » bio-refining » de-inking e Value proposition » increase production yields — significant cost-savings for customers » improve paper quality — competitive advantage » r
Slide 14: Bio-Bleaching
Bio-Bleaching e Dyadic’s bio-bleaching enzymes are on the market today » Used continuously over last two years » used in 12 pulp mills » have successfully treated 1,500,000 tons of pulp e Show significant economic and environmental benefits » Lower production costs » Reduction in hazardous chemical
Slide 15: Bio-Refining
Bio-Refining e Six plants online within last four months » Use of old corrugated cardboard (OCC) to make liner board » OCC requires refining to prepare fiber for processing e Value Proposition » Reduced energy consumption by up to 60% or line speed increase of more than 10% » Increased sheet strengt
Slide 16: $300 million market - Animal Feed
$300 million market - Animal Feed* e Thermostability » enzyme survives pelletizing temperatures a) ‘Feed Enzyme Thermostability » enables alternative application methods e Greater conversion of feed into energy » allows substitution of lower cost grain » provides proven value in layer & broiler feed
Slide 17: BioSciences Business
Slide 18: Growth of Therapeutic Proteins
Growth of Therapeutic Proteins e Therapeutic proteins — the fastest growth area of the pharma industry e Expected average annual growth rate of 12% e Expected market size for protein drugs — $71 billion in 2008 from $41 billion in 2003* e Inefficient and difficult methods for producing sufficient cl
Slide 19: The Antibody Opportunity
The Antibody Opportunity * 16 antibodies on the market * 250 antibodies in the pipeline * $5.4 billion market in 2002 + $16.7 billion expected market he size in 2008* af Pa The C1 solution — ¢ Rapid production of clinical quantities ¢ Rapid, reliable, affordable, scale-up and commercial production ¢
Slide 20: Value Proposition
Value Proposition Increased probability of R&D success Shortened R&D timeline to product commercialization » Integrated approach maximizes probability of commercial success » Increased profits through shortened time to market Reactivation of shelved drug candidates Enable development of follow-on bi
Slide 21: Management and Collaborations
Management and Collaborations
Slide 22: Management Team
Management Team Total # years Experience Previous Experience President, CEO, Founder 27 Entrepreneur CFO 25 Boca Resorts, Alamo National, Gerald Stevens, US Diagnostic EVP, Industrial Enzymes 30 Genencor, Solvay Enzymes, Miles VP, Pulp & Paper 20 Hercules Pulp & Paper, Betz Dearborn VP, Marketing, B
Slide 23: Scientific Advisory Board
Scientific Advisory Board Richard Lerner, M.D. President, The Scripps Research Institute Chairman of Scientific Advisory Board Gerald Fink, Ph.D. Professor and Former Director, The Whitehead Institute, MIT Peter Punt, Ph.D. TNO Voeding — Dept. of Applied Microbiology and Gene Technology Cees van den
Slide 24: Worldwide R & D Network
Worldwide R & D Network Company TNO Voeding (Organization for Applied Scientific Research) Moscow State University & Russian Academy of Sciences Bio-Technical Resources USA Dyadic Nederland BV Netherlands Dyadic Greensboro Laboratory USA Dyadic Asia Hong Kong/ China * Staff includes both Dyadic empl
Slide 25: Patents
Patents e Three issued patents and 57 U.S. and International filed and pending patent applications with broad claims: « C1 Host Technology and their commercial application — C1 Expression System — C1 Screening System * Composition of Matter & Methods for C1 Neutral/Alkaline Cellulases « No royalty s
Slide 26: cf lnchides aD, menufacueing,ofice andsaies; DYADIC”
cf lnchides aD, menufacueing,ofice andsaies; DYADIC”
Dyadic International — Investor Presentation (February 2005) on 6ix